Haemonetics Corporation (HAE)

Return on equity (ROE)

		Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Net income	US$ in thousands	117,558	115,401	43,375	79,469	76,526
Total stockholders’ equity	US$ in thousands	959,959	817,997	749,424	731,670	587,109
ROE		12.25%	14.11%	5.79%	10.86%	13.03%

March 31, 2024 calculation

ROE = Net income ÷ Total stockholders’ equity
= $117,558K ÷ $959,959K
= 12.25%

Haemonetics Corporation's return on equity (ROE) has fluctuated over the past five years, with a gradual decrease from 13.03% in 2020 to 12.25% in 2024. The ROE was highest in 2023 at 14.11% and lowest in 2022 at 5.79%. This variability suggests that the company's ability to generate profit from shareholders' equity has been inconsistent. It is important for investors and stakeholders to further analyze the reasons behind these fluctuations to assess the company's financial performance and sustainability in the long term.